Showing results (1-10 of 414) with videos related to
Sort By:
Pageof 42
Proceedings of the American Thoracic Society|April 8, 2009
KRAS mutations in non-small cell lung cancerGregory J Riely, Jenifer Marks, William PaoClinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 26, 2006
Update on epidermal growth factor receptor mutations in non-small cell lung cancerGregory J Riely, Katerina A Politi, Vincent A Miller, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2008
Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinomaGregory J Riely, Mark G Kris, Daniel Rosenbaum, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2008
Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinomaJames Bean, Gregory J Riely, Marissa Balak, et al.Lung Cancer (Amsterdam, Netherlands)|June 3, 2008
The use of first-generation tyrosine kinase inhibitors in patients with NSCLC and somatic EGFR mutationsGregory J RielyClinical Advances in Hematology & Oncology : H&O|April 9, 2016
Should EGFR tyrosine kinase inhibitors be used in non-small cell lung cancer in the absence of EGFR mutations? No, EGFR TKIs should be reserved for patients with EGFR mutationsGregory J RielyJournal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 27, 2008
Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancerGregory J RielyJournal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 23, 2010
Induction therapy for locally advanced thymomaGregory J Riely, James HuangPlos Medicine|March 2, 2005
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domainWilliam Pao, Vincent A Miller, Katerina A Politi, et al.Cancer|July 20, 2012
Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomasMelissa L Johnson, Camelia S Sima, Jamie Chaft, et al.Pageof 42